

Guidelines for the Programmatic management of TB/HIV in Myanmar

National Tuberculosis Programme

National AIDS Programme

Reprinted in March 2019

Preface

It has been 10 years since TBHIV activities have been started in 7 townships. The operational frame, implementation model and tools for monitoring and evaluation have been developed.

Although there are National Guidelines for HIV and TB that are updated regularly in accordance with WHO guidelines, there has not been a consolidated guideline for the clinical management of TB/HIV patients.

The essential knowledge such as clinical presentations of HIV related TB, differential diagnosis, diagnosis of presumptive extra-pulmonary and disseminated forms of TB, treatment of active TB patients living with HIV are included in this guideline with the contribution from experienced clinicians and skilled program staff.

The brief information about recommended TB/HIV collaborative activities, diagnosis of TB in people living with HIV with flow diagram of XPert testing, infection control, the key indicators, their definitions, and recording forms from program side will permit the attending clinicians to have orientation related to TB/HIV and programmatic management.

I am confident that this guideline will be of considerable help not only to keep the optimal quality of care but also to expand and enhance the scope and scale-up of Myanmar's TB/HIV collaborative activities. The National TB Program and National AIDS Program are thus able to monitor and evaluate the TB/HIV activities by putting the Guidelines for the Programmatic Management of TB/HIV co-infection in Myanmar.

Director (Disease Control) Department of Public Health Ministry of Health The Republic of Union of Myanmar

Acknowledgement

It is to extend appreciation and thankfulness to clinicians from Department of Medical Services, Ministry of Health, Program Managers of National TB Program and National AIDS Program, the Assistance Directors from both programs, Medical Officers from both programs and WHO colleagues who contributed their time, energy and skills for the accomplishment of developing this guideline and to WHO, TB unit for their financial and logistic support.

Contents

List of tables	vi
List of Figures	vi
Abbreviations	/ii
I. TB/HIV collaborative activities	
Table 1: WHO-recommended collaborative TB/HIV activities	1
II. Clinical presentation of HIV-related TB	2
Table 2: Differential diagnosis of TB in adults and children	
II.1. Pulmonary tuberculosis	
Table 3: Clinical features of TB according to the level of immune deficiency	3
Table 4: Differential diagnosis of chest X-ray findings often associated with PTB	3
II.2. Extra-pulmonary tuberculosis	4
II.3. Tuberculosis in children living with HIV	4
Figure 1: How to identify and manage child contacts of infectious adults	
Role of BCG in preventing TB in HIV-infected individuals	
III. HIV testing and counselling	
External Quality Assurance for HIV laboratory testing	5
IV. TB screening in people living with HIV	
Figure 2: Algorithm for TB screening in adults and adolescents living with HIV	6
Figure 3: Algorithm for TB screening in children more than one year of age and	
living with HIV	7
Role of Hospitals in TBHIV collaborative activities	7
V. Diagnosis of TB in people living with HIV	
Figure 5: Diagnosis of Extra-pulmonary TB/MDR-TB in HIV-positive patients1	
V.1. Xpert MTB/RIF or referral to Xpert MTB/RIF is available	
V.2. Xpert MTB/RIF is not available	
V.3. Seriously ill patients	
V.4. Patients with multidrug-resistant tuberculosis	12
VI. Treatment of active TB in patients living with HIV	
VI.1. TB regimens	
Table 8: Essential first-line anti-TB drugs, side effects and interaction with ARVs?	16
Use of anti-TB drugs in special situations	
VI.2. Antiretroviral therapy and TB treatment	
Table 9: Preferred ART regimen in co-administration with TB treatment	18
Table 10: Summary of recommended ART regimens for children who need TB	
treatment	
VI.3. Immune Reconstitution Inflammatory Syndrome1	19
VI.4. Cotrimoxazole preventive therapy and TB treatment	
VI.5. Other HIV prevention interventions, treatment and care	
VII. Isoniazid preventive therapy	21
Table 11: Isoniazid dosage according to body weight Image: Control of the second s	22
VIII. Infection control	
Administrative controls	22
- 	23
Environmental controls	24
Personal protective equipment	
Table 12: Key actions for infection control in health care facilities and congregate	
settings	
IX. Monitoring and evaluation	

TBHIV committee meetings Table 13: TB/HIV indicators and data sources Annex 1 WHO clinical staging of HIV disease in adults, adolescents and children Annex 2: TB Registers and Reporting forms Annex 2.1: Request for examination of biological specimen for TB (TB-05)	.27 .28 .28 .30
Annex 2.1. Request for examination of biological specifien for TB (TB-05)	
Annex 2.2: Laboratory register for smear microscopy and X-pert MTB/RIF (TB-0	
	.31
Annex 2.3: Laboratory register for culture, X-pert MTB/RIF and Drug	22
susceptibility testing	.32
Annex 2.4: TB treatment card (TB-01)	
Annex 2.5: Township TB register (TB-03)	
Township TB register (TB-03) (continued)	
Annex 2.6: Quarterly report on TB case registration (TB-07)	. 30
Annex 2.7: Quarterly report on the outcome of TB patients registered 12-15	20
months earlier (TB-08)	
Annex 3: HIV registers and forms	
Annex 3.1: TB Screening and IPT Evaluation Register	
Annex 3.2: pre-ART register	
Annex 3.3: ART register	
Annex 3.4.1 ART treatment card	
Annex 3.4.2 ART treatment card	
Annex 4: IPT registers and forms	
Annex 4.1: IPT register	
Annex 4.2: IPT card	
Annex 5: Cross referral forms	
Annex 5.1 Three inter link referral form	
Annex 5.2: TB/HIV cross referral form	
Annex 6: Reporting forms for TB/HIV activities	
Annex 6.1: Quarterly Reporting Format for TB/HIV Activities to be reported by	
NTP	
Annex 6.2. Quarterly Report for TB/HIV collaborative activities	
Annex 7. Supervision Check Lists	
Annex 7.1 Supervision Check List for TB/HIV collaborative Activities in TB	
Centres/ Clinics	.53
Annex 7.2 Supervision Check List for TB/HIV collaborative Activities in ART	
Centers/ ART DC site/AIDS-STD team	
Annex 8. Quarterly Consumption Report and Request for HIV Tests	. 55

List of tables

List of Figures

Figure 1: How to identify and manage child contacts of infectious adults	ł
Figure 2: Algorithm for TB screening in adults and adolescents living with HIV6)
Figure 3: Algorithm for TB screening in children more than one year of age and	
living with HIV7	,
Figure 4: Diagnosis of Pulmonary TB/MDR-TB in HIV-positive patients)
Figure 5: Diagnosis of Extra-pulmonary TB/MDR-TB in HIV-positive patients10)

Abbreviations

3TC	Lamivudine
ART	Antiretroviral therapy
ARV	Antiretroviral drug
AZT	Zidovudine
CPT	Co-trimoxazole preventive therapy
CXR	Chest X-ray
E	Ethambutol
_ EFV	Efavirenz
EPTB	Extra-pulmonary tuberculosis
FTC	Emtricitabine
Н	Isoniazid
HIV	Human immunodeficiency virus
IPT	Isoniazid preventive therapy
IRIS	Immune Reconstitution Inflammatory Syndrome
KS	Kaposi sarcoma
LIP	Lymphocytic interstitial pneumonia
LPV	Lopinavir
LPV/r	Ritonavir-boosted lopinavir
MDR-TB	Multidrug-resistant tuberculosis
NAP	National AIDS Programme
NNRTI	Non-nucleoside reverse transcriptase inhibitor
NRTI	Nucleoside reverse transcriptase inhibitor
NTP	National Tuberculosis Programme
PcP	Pneumocystis jiroveci pneumonia
PI	Protease inhibitor
РТВ	Pulmonary tuberculosis
R	Rifampicin
RTV	Ritonavir
S	Streptomycin
ТВ	Tuberculosis
TDF	Tenofovir
TST	Tuberculin skin testing
WHO	World Health Organization
XDR-TB	Extensively drug-resistant tuberculosis
Z	Pyrazinamide

I. TB/HIV collaborative activities

Human Immunodeficiency virus (HIV) is the most powerful factor known to increase the risk of tuberculosis (TB). Persons co-infected with TB and HIV are 20 to 30 times more likely to develop active TB disease than persons without HIV. In developing countries (including Myanmar), TB is the most frequent life-threatening illness and leading cause of death among people living with HIV, including those who are taking antiretroviral therapy (ART). Though TB can occur at any point in the course of progression of HIV infection, the risk rises sharply with worsening immune status. People living with HIV are facing emerging threats of drug-resistant TB such as multidrug resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).

The goal of collaborative TB/HIV activities is to decrease the burden of TB and HIV in people at risk of or affected by both diseases, as recommended by the World Health Organization (Table 1).

The objectives are:

- To establish and strengthen the mechanisms of collaboration and joint management between the national AIDS/STD programme (NAP) and the National Tuberculosis Programme (NTP) for delivering integrated TB and HIV services preferably at the same time and location;
- To reduce the burden of TB in people living with HIV, their families and communities by ensuring the delivery of the *Three I's for HIV/TB* and the early initiation of ART;
- > To reduce the burden of HIV in patients with presumptive and diagnosed TB, their families and communities by providing HIV prevention, diagnosis and treatment.

Α	Establish and strengthen the mechanisms for delivering integrated TB and HIV services
A1	Set up and strengthen a coordinating body for collaborative TB/HIV activities functional at all levels
A2	Determine HIV prevalence among TB patients and TB prevalence among people living with HIV
A3	Carry out joint TB/HIV planning to integrate the delivery of TB and HIV services
A4	Monitor and evaluate collaborative TB/HIV activities
В	Reduce the burden of TB in people living with HIV and initiate early antiretroviral
	therapy (<i>the Four I's for HIV/TB</i>)**
B1	Intensify TB case-finding and ensure high quality anti-tuberculosis treatment
B2	Initiate TB prevention with Isoniazid preventive therapy and early antiretroviral therapy
B3	Ensure control of TB Infection in health-care facilities and congregate settings
С	Reduce the burden of HIV in patients with presumptive and diagnosed TB
C1	Provide HIV testing and counselling to patients with presumptive and diagnosed TB
C2	Provide HIV prevention interventions for patients with presumptive and diagnosed TB
C3	Provide co-trimoxazole preventive therapy for TB patients living with HIV
C4	Ensure HIV prevention interventions, treatment and care for TB patients living with HIV
C5	Provide antiretroviral therapy for TB patients living with HIV

Table 1: WHO-recommended collaborative TB/HIV activities

**Integrated Case Management (the 4th I) from Regional Strategy.

These guidelines emphasize the clinical management of HIV-related TB, i.e. on objectives B and C, as well as on monitoring and evaluation of collaborative TB/HIV activities.

II. Clinical presentation of HIV-related TB

The presentation of TB in people living with HIV depends on the degree of immune suppression and may be confused with other pulmonary or systemic infections (Table 2). TB disease in people living with HIV is more likely to be smear-negative pulmonary or extra-pulmonary compared to HIV-negative people.

In adults		
Acute bacterial	- Shorter history	
pneumonia	- All clients with cough should be referred to exclude TB	
Pneumocystis	- Subacute and insidious onset	
<i>jiroveci</i> pneumonia	- Dry cough, sputum mucoid (if any), progressive exertional dyspnoea	
(PcP)		
Kaposi sarcoma (KS)	-Typical lesions found on the skin and mucous membranes (oral cavity)	
	- Cough, fever, haemoptysis and dyspnoea	
	- Pleural fluid is blood-stained	
	In children	
Acute bacterial	- Pulmonary TB (PTB) in infants can be acute and should be considered when	
pneumonia	there is a poor clinical response to standard antibiotics and a TB contact	
Lymphocytic	- Very common >2 years	
interstitial	- Most difficult diagnosis differential in children	
pneumonitis (LIP)	- Clinically: symmetrical, generalized lymphadenopathy (painless and	
	mobile), bilateral chronic non-tender enlargement, finger clubbing	
	- Chest X-Ray (CXR): bilateral diffuse reticulonodular pattern and enlarged	
	mediastinal/hilar lymph nodes (CXR abnormalities often unilateral with PTB)	
PcP	- Common in HIV-infected children <6 months.	
	- Acute, severe pneumonia	
	- Severe hypoxia	
	- CXR: diffuse interstitial infiltration and hyperinflation	
	- Very unlikely diagnosis of persistent respiratory disease after infancy.	
Bronchiectasis	- Complication of LIP or TB	
	- Cough productive of purulent sputum, sometimes blood-stained	
	- Finger clubbing	
	- Halitosis	

Table 2: Differential	diagnosis of TB i	n adults and children
rable E. Dijjerencial	anagnosis oj re n	n adates and criter cri

II.1. Pulmonary tuberculosis

In the early stages of HIV infection, when immunity is only partially compromised, the features are typical of post-primary pulmonary TB. As immune deficiency advances, people living with HIV present with atypical smear-negative pulmonary disease or extra-pulmonary TB (EPTB). Miliary or disseminated disease is also more common (Table 3).

	Stage of HIV infection	
	Early	Late
Cough We Sputum production wa Weight loss ex		Often resembles primary TB: Weight loss (in presence of wasting syndrome, TB must be excluded) Fever
	Haemoptysis is less common in HIV-positive PTB patients (less cavitation, inflammation and endobronchial irritation)	
Sputum smear result	Often positive	Often negative
CXR findings	- Upper lobe infiltrates - Bilateral infiltrates - Cavitation	 Interstitial infiltrates, especially in lower zones Hilar lymphadenopathy No cavitation No abnormality

 Table 3: Clinical features of TB according to the level of immune deficiency

 Table 4: Differential diagnosis of chest X-ray findings often associated with PTB

CXR finding	Differential diagnosis
Cavitation	Infections
	Bacterial pneumonias
	Nocardiosis
	Melioidosis
	Paragonimiasis
	Lung Abscess
	Some fungal infections
	Non-infectious disease
	Bronchial carcinoma
	Connective tissue disease
	Occupational lung disease
Unilateral infiltration	Pneumonia
	Bronchial carcinoma
Bilateral infiltration	Pneumonia
	Connective tissue disease
	Occupational lung disease
	Sarcoidosis
Mediastinal lymphadenopathy	Lymphoma
	Bronchial carcinoma
	Sarcoidosis

Table 5: Clinical and chest X-ray features of PcP and TE	3
--	---

	Typical of PcP	Typical of TB
Symptoms	Dry cough	Productive cough
	Sputum mucoid (if any)	Purulent sputum
	Dyspnoea	Pleuritic chest pain
		Haemoptysis
Signs	May be normal	Signs of consolidation
	Fine inspiratory crackels	Sings of pleural effusion
Chest X-ray	Bilateral diffuse interstitial	Lobar consolidation
	shadowing	Cavitation
	May be normal	Pleural effusion
		Intrathoracic lymphadenopathy

II.2. Extra-pulmonary tuberculosis

The most common forms of EPTB in people living with HIV include lymphadenitis, pleural effusion, pericardial effusion and meningitis. Presentation of EPTB in people living with HIV is generally not different from that in HIV-negative ones.

II.3. Tuberculosis in children living with HIV

The most common presenting symptoms include cough of more than two weeks duration, weight loss or failure to gain weight and fever. These symptoms are not specific to TB and may be associated with other HIV-related conditions (Table 2). Pulmonary TB is usually smear-negative. HIV-infected children may develop severe PTB (including miliary TB) at any age. Common forms of EPTB include TB meningitis, TB lymphadenitis, TB effusions and spinal TB.




Figure 1: How to identify and manage child contacts of infectious adults

Role of BCG in preventing TB in HIV-infected individuals

Bacille Calmette-Guérin (BCG) is a live attenuated vaccine. The route of injection is intradermal. The usual dose is 0.05 ml in neonates and infants<3 months and 0.1 ml in older children.

The benefit of BCG is in protecting young children against disseminated and severe TB, e.g. TB meningitis and miliary TB. BCG has little or no effect in reducing the number of adult cases of PTB.

It is not known if HIV infection reduced the protection conferred by BCG against TB in children. There is evidence that conversion to a positive tuberculin test after BCG is less frequent in HIV-positive children.

BCG vaccine should not be used in children who are known to be HIV-positive because of the increased risk of severe and often fatal disseminated BCG disease. BCG-induced immune reconstitution inflammatory syndrome (BCG-IRIS) is increasingly reported in infants living with HIV who have started ART early in infancy. BCG-IRIS can cause significant morbidity although - unlike disseminated BCG disease - it is rarely fatal.¹

Guidance on implementation of BCG vaccination for HIV exposed babies

- (A) Early Infant Diagnosis (either Dry Blood Spot or Viral Load Testing) is available
 - BCG vaccination needs to be deferred until the result is known. If baby is infected with HIV, BCG should not be given.
- (B) Early Infant Diagnosis (either Dry Blood Spot or Viral Load Testing) is not available
 - BCG should not be given to the infants whose HIV infection status is unknown but who have signs or reported symptoms suggestive of HIV infection and who are born to HIV-positive mothers.
 - BCG should be given to the infants whose HIV infection status is unknown but who have no signs or reported symptoms suggestive of HIV infection and who are born to HIV-positive mothers.

III. HIV testing and counselling

People access HIV treatment, care and prevention through the gateway of HIV testing and counselling. The vast majority of people living with HIV does not know their HIV status and seek health care from general service providers. HIV testing and counselling for people diagnosed with or suspected of TB disease offers an entry point for a continuum of prevention, care, support and treatment for HIV and for TB.

Provider-initiated HIV testing is recommended for all patients with suspected and diagnosed TB as well as to partners of known HIV-positive TB patients.

HIV testing and counselling should adhere to the *five C's*:

- Consent
- Confidentiality
- Counselling
- Correct test results; and
- Connections to care, treatment and prevention services.

See the guidelines for the clinical management of HIV infection in Myanmar for more information.


External Quality Assurance for HIV laboratory testing


In collaboration with National Health Laboratory (NHL), all the laboratories that perform HIV testing are enrolled for External Quality Assurance. Each laboratory sends samples with test results (Panel testing) every 6 monthly and NHL provides feedback regularly.

¹ Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed. Geneva, World Health Organization, 2014.

IV. TB screening in people living with HIV

All people living with HIV should be regularly screened for TB using a symptom-based algorithm consisting of current cough, fever, weight loss and night sweats (Figure 2).







¹ Contraindications include: active acute or chronic hepatitis, regular and heavy alcohol consumption, symptoms of peripheral neuropathy.

 2 IPT can be given regardless of prior TB treatment history. For patients with prior IPT history more than two years ago, IPT can be considered again if the patient has risk of developing TB, for example, close contact with TB cases.

In children living with HIV, the symptom-based algorithm consists of poor weight gain, fever or current cough or contact history with a TB case (Figure 3). Poor weight gain in children is defined as reported weight loss or confirmed weight loss (>5%) since the last visit or growth curve flattening or very low weight (weight for age ≤ 3 z score) or underweight (weight for age ≤ 2 z score).





¹ All children (including infants less than one year of age) should be provided with IPT if they have a history of household contact with a TB case.

² Poor weight gain is defined as reported weight loss or confirmed weight loss (>5%) since the last visit or growth curve flattening or very low weight (weight for age ≤ 3 z score) or underweight (weight for age ≤ 2 z score).

³ Contraindications include active acute or chronic hepatitis, symptoms of peripheral neuropathy.

⁴ In general, IPT is not indicated for the HIV infected children who had completed prior IPT or treated for TB. However, IPT may be considered as individual case, for those at high risk of becoming re-infected and progressing to TB disease.

Children, adolescents and adults living with HIV should be screened at the time of initial presentation for HIV care and at every visit to a health facility or contact with a health-care worker afterwards.

Role of Hospitals in TBHIV collaborative activities

Not only NAP's clinics, the general hospitals and district hospitals play a major role in HIV care component. They are the ART centres where all eligible patients are enrolled to initiate ART. The baseline investigations and follow up investigations for HIV patients are done at the laboratories of those hospitals. The clinicians of the hospital provide clinical consultations whereas NAP supports drug supply and other logistics, data captures, recording and reporting. When patients are stabilized after 6 to 12 months initiation of ART, they are transferred out to the ART decentralized sites close to the patients' residence. The ART decentralized sites which are township hospitals or township health departments provide chronic HIV care and referred back to ART centres whenever it is necessary.

ART centres and ART decentralized sites have to do TB symptom screening at each and every visit of HIV patients, implement TB prevention activities with IPT to all eligible patients. Moreover, they need to record and report the TBHIV collaborative activities of their sites in coordination with respective disease control team of the District/ State/ Region.

V. Diagnosis of TB in people living with HIV


Children, adolescents and adults living with HIV who have a positive TB screening may have active TB and should be evaluated for TB and other diseases (Figures 2 and 3). Since smear-negative pulmonary TB and EPTB are associated with poor treatment outcomes and excessive early mortality among people living with HIV, all efforts should be made to ascertain HIV status and to expedite TB diagnostic process. If extra pulmonary TB is suspected, diagnostic processes should be expedited using all available and appropriate investigations, including mycobacterial culture.²

Xpert MTB/RIF is recommended as the primary TB diagnostic test among people living with HIV in order to speed up TB diagnosis and to recognize MDR-TB in people living with HIV. MDR-TB is defined as TB resistant to at least isoniazid and rifampicin. Patients with both HIV and MDR-TB face complicated management, fewer treatment options and poorer treatment outcomes.

The diagnostic work-up for TB depends on the availability of Xpert MTB/RIF


² Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings. Geneva, World Health Organization, 2007.

Figure 4: Diagnosis of Pulmonary TB/MDR-TB in HIV-positive patients



Diagnosis of TB/MDR-TB in HIV-positive patients

Figure 5: Diagnosis of Extra-pulmonary TB/MDR-TB in HIV-positive patients



Diagnosis of TB/MDR-TB in patients with risk factor for TB from specimens other than sputum

V.1. Xpert MTB/RIF or referral to Xpert MTB/RIF is available

- If Xpert MTB/RIF is positive, treat for TB.
- If resistance to rifampicin is detected, follow the algorithm of MDR-TB, treat the patient for MDR- TB (see guidelines for the management of Drug Resistant Tuberculosis (DR-TB) in Myanmar (February 2017).
- If Xpert MTB/RIF is negative, pulmonary TB is less likely. Clinical assessment and appropriate investigations which are summarized in Table 7 are important to decide whether the patient may have extra-pulmonary TB.

V.2. Xpert MTB/RIF is not available

- Specimen transportation to Xpert MTB/RIF sites
- Investigations include sputum examination, chest X-ray (CXR), sputum culture and investigations to assess EPTB (Table 7).

Patients who are not treated for TB should receive either a broad-based antibiotic (but not a fluoroquinolone) to treat bacterial infection or treatment for PcP (Table 2). Assessment of patient's response should be established in either the TB or the HIV services. For patients with immediate response to PcP or antibiotic treatment, continued vigilance is necessary to exclude superimposed TB. Those patients with an unsatisfactory response to treatment for PcP or bacterial pneumonia should be reassessed both clinically and bacteriologically for TB.

V.3. Seriously ill patients

A patient is classified as seriously ill if one or more of the following danger signs are present:

- Unable to walk unaided
- Respiratory rate >30 per minute
- Temperature >39 °C
- Heart rate >120 per minute.

The highest priority in a seriously ill patient is to provide the patient with life-sustaining supportive therapy, such as oxygen and parenteral antibiotics. If life-sustaining therapy is not available at the initial point of care, the patient should be transferred immediately to a higher level facility before further diagnostic testing.

When immediate referral is not possible, the following measures should be undertaken in the peripheral health facility:

- Immediate start with broad-spectrum parenteral antibiotics for bacterial infection and perform Xpert MTB/RIF, if available. Safe injection practices should be strictly followed. If indicated, PcP treatment should be considered (see guidelines for the clinical management of HIV infection in Myanmar).
- If the diagnosis of TB is confirmed by Xpert MTB/RIF, start anti-TB treatment. The antibiotic treatment initiated previously should be continued and completed.
- If Xpert MTB/RIF is negative, response to parenteral antibiotics should be assessed after three days into treatment. If there is no improvement, empiric TB treatment should be initiated if strong clinical suspicion of TB remains. The initial antibiotic course should be continued and completed. Patients should be referred to the next level of care to confirm the diagnosis of TB and for HIV care. If referral is not possible, TB treatment should be completed.

If referral to a higher-level facility is possible, the patient should be managed as an emergency. If Xpert MTB/RIF result is negative, additional investigations should be performed to investigate for extra-pulmonary TB and other diseases. These additional investigations may include CXR, liquid culture of sputum, lymph node aspiration for acid-fast bacilli microscopy and culture, and abdominal ultrasound. Depending on the local epidemiology, non-tuberculous mycobacterial infection should be considered in the differential diagnosis of patients who have a negative Xpert MTB/RIF but a sputum or extra-pulmonary specimen with acid-fast bacilli.

Whatever the results of TB investigations, patients should undergo HIV clinical staging and treatment assessment for co-trimoxazole preventive therapy (CPT) and ART.

V.4. Patients with multidrug-resistant tuberculosis

Rifampicin resistance is a reliable proxy for MDR-TB in high burden settings. HIV patients with resistance to rifampicin detected by Xpert MTB/RIF should therefore be started on appropriate MDR-TB treatment immediately according to guidelines for the management of Drug Resistant Tuberculosis (DR-TB) in Myanmar (February 2017).

Concomitant treatment of drug-resistant TB and HIV

ART in HIV/TB co-infected patients improves survival and slows progression to AIDS. As mentioned above, ART should be initiated in all MDR-TB/HIV patients as soon as MDR-TB treatment is tolerated. This is usually within the first two months of treatment.

If the patient is already on ART and diagnosed with MDR-TB, investigation to see if the patient may be failing ART should be done. This includes clinical evaluation, CD4 count evaluation and, whenever possible, viral load testing. If there is evidence of ART failure, a new ART regimen should be initiated.

Issue	egarding the treatment of MDR-1B/HIV co-infection Comment
Potential drug	Rifampicins lower the levels of protease inhibitors and non-
interactions in the treatment of drug-	nucleoside reverse transcriptase inhibitors, especially nevirapine, contributing to the development of resistance to these drugs.
resistant TB and HIV	• ARVs increase the level of rifampicin and the risk of toxicity.
	 Non-enteric coated didanosine contains an aluminium/magnesium-based acid that if given together with FQs may result in decreased FQ absorption. It should be given six hours before or two hours after FQs.
Potential drug toxicity in the	 Peripheral neuropathy may be caused by stavudine, aminoglycoside, cycloserine, pyrazinamide.
treatment of drug- resistant TB and HIV	• Cutaneous reactions by nevirapine and cotrimoxazole are more common.
	 Gastrointestinal effects are more common with the higher pill burden.
	• Renal toxicity can be increased by the use of the injectables and tenofovir. Avoid the use of tenofovir with the injectable agent (only if AZT resistance is present should tenofovir be used, and with very close monitoring of the renal function - every 1 to 2 weeks).
	• Neuropsychiatric effects can be increased with cycloserine and efavirenz, but these drugs can be used together.
Immune reconstitution Inflammatory syndrome	• This syndrome can present as a paradoxical worsening of the patient's clinical status.
(IRIS)	• It generally presents within three months of the initiation of ART and more common with a low CD4 cell count (<50 cells/mm3).
	 Management of IRIS is complex and depends on the clinical status of the patient and the site and extent of involvement. Various treatment modalities have been employed, including nonsteroidal anti-inflammatory drugs (NSAIDs) in mild disease and corticosteroids in moderate to severe disease.
	• Most patients can be treated without interruption of ART.
Monitoring of drug- resistant TB and HIV in	• When treatment for MDR-TB is administered, DOT of ART should be included.
co-infected patients	• Monitoring of CXR, smears and cultures is the same as for HIV- negative patients. Monitoring of creatinine and potassium should be increased to every two weeks while on the injectable agent.
	• For MDR-TB patients, in the case of treatment failure both TB treatment and ART regimen should be re-evaluated.
Implications of HIV for MDR-TB infection control	 MDR-TB outbreaks have overwhelmingly involved HIV-positive populations, commonly nosocomial transmissions. Delay in recognition of MDR-TB, prolonged periods of infectiousness, crowded wards, and mixing of TB and HIV patients all contribute to MDR-TB outbreaks that affect both HIV-positive and HIV- negative patients. Hospitals must implement adequate infection control precautions significantly to reduce nosocomial transmission.

Table 6: Special issues regarding the treatment of MDR-TB/HIV co-infection

Lymphadenitis	Pleural effusion	Pericardial effusion	Meningitis	Disseminated TB	
	Essential investigations				
 > HIV test (rapid if possible) > Sputum smears if coughing > Needle aspirate for AFB (18 to 21 gauge) 	 > HIV test (rapid if possible) > CXR > Sputum smears if coughing > Aspirate & inspect fluid > Differential white blood cell count and protein determination (if possible) of aspirate 	 > HIV test (rapid if possible) > CXR > Sputum smears if coughing > Cardiac ultrasound (ideally) > Electrocardiogram if ultrasound not available 	 > HIV test (rapid if possible) > Lumbar puncture > Microscopy (Gram stain and AFB)/protein/ glucose in cerebrospinal fluid > Cryptococcal antigen/stain > Sputum smears if coughing 	 > HIV test (rapid if possible) > CXR > Malaria blood film > Sputum smears if coughing > Blood cultures, full blood count and cryptococcal antigen 	
	Hig	h suspicion of tuberculosis if			
 2 cm or more in size Asymmetrical/localized Painless swelling Firm/fluctuant/fistulated Cervical location Weight loss, night sweats, fever 	 Unilateral effusion Aspirate of fluid is: Clear and straw coloured and Clots on standing in a tube without anticoagulants Weight loss, night sweats, fever Evidence for tuberculosis elsewhere 	 Lung fields clear (but may have bilateral pleural effusion) Weight loss, night sweats, fever Evidence of tuberculosis elsewhere 	 Weight loss, night sweats, fever Cerebrospinal fluid clear with high protein, low glucose and lymphocytes Cryptococcal antigen (or India ink and fungal culture) negative in cerebrospinal fluid Evidence of tuberculosis elsewhere 	 Weight loss, fever and cough Abnormal CXR (which can include miliary pattern) Large spleen/liver Night sweats Anaemia 	

Table 7: Diagnosis of presumptive extra-pulmonary TB and disseminated forms of TB

Lymphadenitis	Pleural effusion	Pericardial effusion	Meningitis	Disseminated TB
	Findings tha	t suggest a non-tuberculosis dia	gnosis	
 KS in skin or mouth (probable KS nodes) Symmetrical (probable lymphoma or HIV lymphadenopathy) Tender, inflamed, purulent (bacterial or fungal) Site other than cervical 	 Bilateral effusion (possible heart failure or pneumonia) Clinical KS/other malignancy Aspirate of fluid is: Cloudy/pus (probable empyema) Fails to clot (does not exclude tuberculosis, but send fluid for protein and differential cell count, and consider heart failure) 	 Streaky shadowing of lung fields and/or heart shape not symmetrical (probable heart failure) High blood pressure Electrocardiogram suggests another cause for enlarged heart (e.g. high blood pressure, valve disease, dilated cardiomyopathy) Murmur (probable valvular disease) Rigors (probable bacterial pericarditis) 	 Cerebrospinal fluid cloudy or neutrophils on microscopy (probably bacterial) Cryptococcal tests positive Rapid onset Very high cerebrospinal fluid pressure (probably cryptococcal) 	 Also consider Salmonella, pneumococcus, malaria, cryptococcus: Rigors Very breathless (respiratory rate 30/min) Severe diarrhoea Blood in stool Positive cryptococcal antigen, malaria smear or likely pathogen isolated from blood culture

VI. Treatment of active TB in patients living with HIV

VI.1.TB regimens

New TB patients living with HIV should receive a TB regimen on a daily schedule containing six months of rifampicin: 2HRZE/4RH [two months of isoniazid, rifampicin, pyrazinamide and ethambutol followed by four months of rifampicin and isoniazid].

Retreatment cases who are not found to have resistance to rifampicin or isoniazid and rifampicin should be managed with a retreatment regimen containing first-line drugs: 2HRZES/1HRZE/5HRE [two months of isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin, followed by one month of isoniazid, rifampicin, pyrazinamide and ethambutol, followed by five months of rifampicin, isoniazid and ethambutol].

Retreatment TB cases who are found to have resistance to rifampicin or isoniazid and rifampicin should be enrolled in the MDR-TB programme on an MDR-TB regimen (see guidelines for the management of MDR-TB in Myanmar).

TB treatment regimen in children living with HIV depends on the TB presentation:

- 2HRZE/4HR in children with clinically diagnosed or bacteriologically confirmed PTB or peripheral TB lymphadenopathy
- 2HRZE(S)/10HR in children with clinically diagnosed or bacteriologically confirmed TB meningitis and
- 2HRZE/10HR in children with clinically diagnosed or bacteriologically confirmed osteo-articular TB.

First line anti- TB drug	Main side effects	Drug interaction with ARVs
lsoniazid	 Peripheral neuropathy Hepatitis 	 Stavudine (although not to be used anymore) also causes peripheral neuropathy
Rifampicin	 Gastro-intestinal: nausea, anorexia, vomiting, abdominal pain Hepatitis Coloration of all body secretions (red or orange) 	 Rifampicin lowers the level of PIs and NNRTIs (especially nevirapine), contributing to the development of resistance to these drugs ARVs increase the level of rifampicin and the risk of toxicity Rifampicin may be replaced by rifabutin in patients on PIs, where available
Ethambutol	 Optic neuritis: decreased acuity, restricted field of vision, loss of colour discrimination 	
Pyrazinamide	- Joint pains - Hepatitis	

Table 8: Essential	first-line anti-TB drug	s, side effects and interaction with A	ARVs
Tuble 0. Essentiat	jii se une une i b uiug.	s, side effects and miteraction with p	1/1

Use of anti-TB drugs in special situations

- **Pregnancy:** streptomycin should not be given in pregnancy as it can cause permanent deafness in the baby. Second-line drugs such as fluoroquinolones, ethionamide and prothionamide are teratogenic and should not be used.
- **Renal failure:** patients with severe renal failure should receive pyridoxine with isoniazid to prevent peripheral neuropathy. Streptomycin and ethambutol should be avoided or given in reduced dosage. 2HRZ/4HR is the safest regimen

- Liver disease: most anti-TB drugs can give liver disease and, therefore, care is needed. Pyrazinamide should not be given as it is the most hepatotoxic. Isoniazid and rifampicin plus one or two non-hepatotoxic drugs (such as ethambutol or streptomycin) can be given for a total duration of eight months. Recommended regimens are 2SRHE/6HE or 2SHE/10HE or 2SE+FQ (Levofloxacin)/10 E+FQ (Levofloxacin).

VI.2.Antiretroviral therapy and TB treatment

ART should be started in all TB patients, including those with drug-resistant TB, irrespective of CD4 count. TB treatment should be initiated first, followed by ART as soon as possible within the first eight weeks of TB treatment. Patients with profound immunosuppression (such as CD4 counts <50 cells/mm³) should receive ART immediately within the first two weeks of initiating TB treatment.

Similarly, ART should be started in any child living with HIV presenting active TB disease as soon as possible within eight weeks following initiation of anti-TB treatment irrespective of CD4 count and clinical stage.

Preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone includes TDF/3TC (or FTC) since the combination of TDF/3TC/EFZ is available as once daily, is less frequently associated with severe adverse events and has a good virological and treatment response.

The alternative NRTI backbone is AZT/3TC. AZT is associated with anaemia which is most common in the first six months of treatment but can occur at any time. In advanced HIV disease, it may be advisable to avoid AZT.

Rifampicin is a potent inducer of liver cytochrome P_{450} system and considerably decreases almost all PIs and NVP drug levels. Therefore, EFV should be used as the preferred nonnucleoside reverse transcriptase inhibitor (NNRTI) in patients starting ART while on TB treatment.

After failure to a first-line NNRTI regimen, a boosted protease inhibitor (PI) plus two NRTIs are recommended for second-line ART. Boosted lopinavir (LPV/r) may be used in the co-administration with rifampicin. In this case, adjusted dose is necessary: LPV 800 mg + RTV 200 mg twice daily or LPV 400 mg + RTV 400 mg twice daily with close monitoring of liver function. As an alternative, rifabutin (where available) may be used at the dose of 150mg per day or 300mg thrice in a week when co-administered with standard doses of LPV/r.

 Table 9: Preferred ART regimen in co-administration with TB treatment

First line ART regimen		
Preferred NRTI backbone: TDF 245 mg OD + 3TC 300mg OD (or FTC 200mg OD)	EFV 600mg OD at night with rifampicin 600mg OD	
Alternative NRTI backbone: AZT 300mg BID + 3TC 300mg OD (or FTC 200mg OD)		
Second line ART regimen		
If TDF used in first-line therapy: AZT 300mg BID + 3TC 300mg OD (or FTC 200mg OD)	LPV/r 400mg/400mg BID or LPV/r 800mg/200mg BID with Rifampicin 600mg OD,	
If AZT used in first line therapy: TDF 245 mg OD + 3TC 300mg OD (or FTC 200mg OD)	LPV/r 400mg/100mg with Rifabutin 150mg OD	

In patients on MDR-TB treatment, the preferred NRTI backbone includes AZT since the renal toxicity of TDF can increase in association with injectable drugs. If AZT resistance is present, TDF may be used with very close monitoring of the renal function. i.e. every 1 to 2 weeks.

Co-treatment in children less than three years of age with TB disease is challenging as EFV is contra-indicated in this population. Triple nucleoside-based therapy may be a suitable option to avoid interactions between rifampicin and LPV/r or NVP in young children.

Recommended regimens for children initiating ART while on TB treatment			
<3 years		Triple NRTI (AZT + 3TC + ABC)	
3 years and older		Two NRTIS + EFV Or Triple NRTI (AZT+3TC+ABC)	
Recommended re	gimen for children	initiating TB treatment while receiving ART	
Child on a standard NNRTI-based regimen two NRTIs + EFV or NVP)	<3 years	Continue NVP, ensuring the dose is 200mg/m ² Or Triple NRTI (AZT + 3TC + ABC)	
	3 years and older	If the child is receiving EFV, continue the same regimen If the child is receiving NVP, substitute with EFV Or Triple NRTI (AZT + 3TC + ABC)	
Child on a standard PI- based regimen (two NRTIs + LPV/r)	< 3 years	Triple NRTI (AZT + 3TC + ABC) Or Continue LPV/r, adding RTV to achieve the full therapeutic dose	
	3 years and older	If the child has no history of failure of an NNRTI- based regimen: Substitute with EFV Or Triple NRTI (AZT + 3TC + ABC) Or Continue LPV/r, adding RTV to achieve the full therapeutic dose If the child has a history of failure of an NNRTI- based regimen: Triple NRTI (AZT + 3TC + ABC) Or Continue LPV/r, adding RTV to achieve the full therapeutic dose Consider consultation with experts for constructing a second-line regimen	

Table 10: Summary of recommended ART regimens for children who need TB treatment	Table 10: Summary	of recommended ART	regimens for childre	en who need TB treatment
--	-------------------	--------------------	----------------------	--------------------------

ART greatly improves the survival and the quality of life of HIV-infected TB patients and prevents HIV and TB transmission among people living with HIV. It should be considered as part of HIV and TB treatment and prevention. ART is a powerful strategy to reduce TB incidence among people living with HIV across a broad range of CD4 cell-counts. All efforts should be made to timely initiate ART among eligible HIV positive patients.

ART should be offered preferably within integrated services or within TB facilities. Effective referral to HIV services remains an alternative but relies on sound referral systems and patients' ability to afford other costs such as transport and lost wages.

VI.3.Immune Reconstitution Inflammatory Syndrome

TB-associated Immune Reconstitution Inflammatory Syndrome (TB-IRIS) is a recognized complication of ART. It has two forms:

- **Paradoxical TB-IRIS** that occurs when patients receiving treatment for TB are put on ART and develop an immune-mediated clinical deterioration. It has been reported in 8%-43% of TB patients starting ART. A key differential diagnosis is for drug-resistant TB, which may similarly present with an initial clinical improvement followed by deterioration.
- **Unmasking TB-IRIS** that develops in a smaller fraction of patients not on TB treatment. Patients starting ART develop treatment-associated TB with inflammatory symptoms in the first few months. Unmasking TB-IRIS seems to be triggered by antiretroviral-induced immune recovery and may account for more than 30% of cases of TB presenting during the first months of ART.

TB-IRIS is associated with fever, enlargement of lymph nodes sometimes with liquefactive necrosis, worsening pulmonary infiltrates, pleural or pericardial effusion, expanding central nervous system tuberculomas or appearance of TB meningitis. In managing IRIS, both TB treatment and ART are continued. The excessive inflammatory response is controlled by prednisone. A double-blind placebo-controlled trial of prednisone for TB-IRIS showed that a four-week course of prednisone at the time of diagnosis of paradoxical TB-IRIS reduced the duration of hospitalization and need for procedures, without an excess of adverse events or severe infections.

Risk factors for IRIS include:

- Very low CD4 count at the start of ART
- Very high HIV viral load and very rapid fall in viral load after the start of ART
- Treatment naïve at the start of TB treatment,
- Short interval between TB treatment and ART.

However, since most episodes of TB-IRIS are self-limiting and not associated with significant mortality, the risk of TB-IRIS must be balanced against the benefit of early initiation of ART in patients with advanced immunosuppression.

VI.4. Cotrimoxazole preventive therapy and TB treatment

Pulmonary TB disease is a WHO stage 3 clinical condition (Annex 1). Therefore, routine cotrimoxazole preventive therapy (CPT) should be administered in people living with HIV with all TB diseases regardless of CD4 count.

Cotrimoxazole is a broad spectrum antimicrobial agent that prevents PcP, toxoplasmosis and a range of secondary bacterial and parasitic infections in eligible adults and children living with HIV. CPT is a simple, well-tolerated and cost-effective intervention for people living with HIV and can be administered concomitantly to ART and TB treatment.

One double-strength tablet daily of co-trimoxazole (960 mg) is recommended. Skin reaction is the most common side effect with cotrimoxazole. Erythema and maculopapular rash may be observed and treated with anti-histaminics. In case of vesiculation, mucosal ulceration and exfoliative dermatitis, CPT should be discontinued immediately and permanently, and replaced by dapsone 100 mg a day although it is less effective than CPT. Other side effects include bone marrow toxicity and hepatotoxicity. Cotrimoxazole-related adverse events are not common and typically occur within the first weeks of starting prophylaxis.

VI.5.Other HIV prevention interventions, treatment and care

Prevention of HIV includes interventions to:

- Prevent sexual transmission such as use of male and female condoms, male circumcision, HIV testing and counselling including couples counselling and testing, early ART and ART for serodiscordant couples. Prevent vertical transmission of HIV through ART initiation at least for the duration of mother-to-child transmission risk, i.e. pregnancy, delivery and breastfeeding period. Women meeting ART eligibility criteria should continue lifelong ART.
- Prevent transmission among injecting drug users by ensuring access to sterile injecting equipment, opioid substitution therapy and outreach services to reduce the risk of HIV transmission and other negative health effects of injecting drug use; combined with behavioural interventions and brief interventions to prevent hazardous alcohol use and use of other psychostimulants.
- Prevent HIV transmission at the workplace through primary prevention measures such as standard precautions, injection safety, blood safety and safe waste disposal, as well as secondary prevention measures such as occupational post-exposure prophylaxis.

A comprehensive package of diagnosis, treatment and care interventions (continuum of care) should be provided to all people living with HIV, ideally starting well before the need for ART. **Pre-ART care** includes:

- Regular assessment of the clinical and immunological stages of infection (Annex 1),
- Treatment of latent TB Infection (IPT)
- Prevention and treatment of opportunistic infections,
- Preparation for adherence to ART,
- Nutritional support, provision of safe water, sanitation and hygiene,
- Psychosocial support, and prevention and management of mental health disorders, including alcohol and other substance use.

VII. Isoniazid preventive therapy

Isoniazid is given to individuals in order to prevent progression to active disease. Exclusion of active TB is important before isoniazid preventive therapy (IPT) is started (Figures 2 and 3). All people living with HIV who have a negative screening for TB disease using the clinical symptom-based algorithm describe above, i.e. who do not report any of current cough, fever, weight loss and night sweats, are unlikely to have active TB and can be reliably initiated on IPT. IPT should be given for six months at the dose of 300 mg per day. Pyridoxine (vitamin B6) supplementation to prevent isoniazid-related peripheral neuropathy is recommended at a dose of 25 mg daily.

IPT should be given irrespective of the route of HIV transmission (including injecting drug use), of the degree of immune suppression, to those on ART, and to pregnant women. Pregnant women living with HIV are at risk for TB which can impact on maternal and perinatal outcomes. These can range from death of the mother and the new-born to prematurity and low birth weight of the new-born. The clinical algorithm should therefore be introduced into maternal services in order to prevent, diagnose and treat TB in pregnant women and women of childbearing age. Among injecting drug users, TB screening

and IPT should be combined to harm reduction services including safe needles and syringes programmes.

Children living with HIV older than 12 months of age who do not have poor weight gain, fever or current cough and have no contact with a TB case are unlikely to have active TB disease and should receive IPT for six months at the dosage of 10 mg/kg/day (Table 11). In children with HIV who are less than 12 months of age, only those who have contact with a TB case and who are evaluated for TB using investigations such as CXR should receive six months of IPT if the evaluation shows no TB disease.

Weight range (kg)	Dose given (mg)	100 mg tab
<5	50	1/2
5 - 9.9	100	1
10 - 13.9	150	1 ½
14-19.9	200	2
20-24.9	250	2 1/2
≥25	300	3

 Table 11: Isoniazid dosage according to body weight

Tuberculin skin test (TST) and CXR are not a requirement for initiating IPT in people living with HIV. Providing IPT to people living with HIV does not increase the risk of developing isoniazid-resistant TB. Concerns regarding the development of INH resistance should not be a barrier to providing IPT.

Exclusion criteria to IPT include: active liver disease, peripheral neuropathy, and heavy alcoholic consumption.

VIII. Infection control

People living with HIV are at significant risk of acquiring TB in health care facilities and congregate settings. HIV promotes progression to active TB both in people with recently acquired infection or with latent *M. tuberculosis* infection.

The infection control plan of each health facility should include administrative, environmental and personal protection measures to reduce the transmission of TB and surveillance of TB disease among medical and non-medical staff (Table 12).

Health care workers, workers in congregate settings and carers living with HIV should be provided with CPT, ART and IPT if they are eligible.

Administrative controls

Administrative controls are aimed at preventing droplet nuclei from being generated and reducing exposure. The NTP/NAP should ensure that any outpatient care facilities have a system to identify persons with respiratory symptoms in waiting areas of out-patient departments and emergency units. These persons should be given priority for care in order to minimize the time spent in the health facility. Additionally, they should be instructed to cover their mouth and nose when coughing and moved to a separate waiting area, if possible. If TB is presumed, diagnostic delays should be minimized by reducing sputum turn-around time, use of rapid diagnostics, carrying out investigations in parallel rather than in sequence, and by using smear-negative algorithms.

A person with presumed MDR-TB in need of other medical tests or procedures should be accompanied to other departments, and not be left in a waiting area. The person should wear a surgical mask or cover mouth and nose with a tissue. For patients diagnosed with TB, prompt initiation of treatment should be ensured.

Each health facility should have an infection control plan or a set of standard operation procedures which (i) includes the health staff responsible for identifying persons with respiratory symptoms; and (ii) outlines the procedures to be followed to ensure separation, cough hygiene, and fast-tracking.

Triage & Separate

Identify people with respiratory symptoms



Administrative controls

Estimated number of bacilli liberated by:


- Talking: 0-200
- Coughing: 0-3,500
- Sneezing: 4,500-1,000,000


(Wells 1934, Duguid 1945, Wells/Riley 1953 et.al)



Environmental controls

Environmental controls include methods to reduce the concentration of infectious respiratory aerosols (i.e. droplet nuclei) in the air; and methods to control the direction of infectious air. A variety of simple to complex environmental controls can be used to reduce the number of aerosolized infectious droplet nuclei in the work environment. The simplest and least expensive technique is to remove and dilute the air from TB patient areas away from patients without TB by maximizing natural ventilation through open windows and doors. More complex and costly methods involve the use of mechanical ventilation (e.g. window fans, exhaust ventilation systems) in isolation rooms or wards to produce negative pressure and prevent contaminated air from escaping into hallways and other surrounding areas. Additional complex and costly methods include air filtration to remove infectious particles and ultraviolet germicidal irradiation to kill M. tuberculosis organisms. Given that Myanmar has a tropical climate in most parts of the country and for most time of the year, it is possible to take advantage of natural ventilation, e.g. utilizing wind to provide air exchanges and reduce the concentration of droplet nuclei. When constructing or renovating space, consideration should be given to placing windows and openings on opposite walls to enhance cross-ventilation, as well as to the prevailing wind direction. Natural ventilation can be enhanced with the use of exhaust fans, if necessary.





under the door

Personal protective equipment

Personal protective equipment (particulate respirators) should be used together with administrative and environmental controls in situations where there is an increased risk of transmission Respirators that meet standards N95, FFP2 or higher and are properly used may provide health workers with additional protection from TB. Prioritization will be given to MDR-TB wards and centres, reference laboratories, and high volume diagnostic centres, e.g. at the State/Regional level.

Personal protective equipment

Respirators



Storage of respirator





 Table 12: Key actions for infection control in health care facilities and congregate settings

Measure	Key actions
Administrative (facility-level infection control committee and protocols)	 A triage system to identify people suspected of having TB Separate people with suspected or confirmed TB Cough etiquette and respiratory hygiene Rapid diagnosis with Xpert MTB/RIF (with prompt treatment of active TB)
Environmental	 Ventilation (natural) Ventilation (mechanical) Upper-room ultraviolet germicidal irradiation, where present
Personal	 Spend as much time as possible outside Cough etiquette Sleep alone while smear-positive Avoid congregate settings and public transport while smear-positive Use of surgical mask by TB patient
Health workers and carers	 Surveillance and information Package of care for HIV-positive workers (ART and IPT) Protective equipment (particulate respirator masks that meet or exceed N95 standards) Relocation for health care workers living with HIV to a lower-risk area of TB transmission

IX. Monitoring and evaluation

Monitoring and evaluation provides the means to assess the delivery, coverage, quality and effectiveness of collaborative TB/HIV activities. It involves collaboration between NAP and NTP, between Medical Care and Public Health, Laboratory and all partners involved in TB/HIV collaborative activities. It deals with the development of referral linkages between the different services and organizations, and joint supervision.

Indicators for TB/HIV collaborative activities are summarized in Table 13. They are collected using TB registers and pre-ART and ART registers based on the WHO Three Interlinked Systems.

TBHIV committee meetings

TBHIV committee meetings at townships level are organized quarterly in order to monitor the activities and to overcome the barriers for the effective implementation of TBHIV collaborative activities. Focal persons from Regional/ district level disease control team (NTP and NAP) participate in those meeting and guide the township team.

Indicator and definition	Data source
	Data source
To be reported by NAP	
percentage of estimated HIV positive incident TB cases that received treatment for TB and HIV.	-
Number of adults and children enrolled in HIV care who had their TB status assessed and recorded during their last visit among all adults and children enrolled in HIV care in the reporting period.	Pre-ART register ART registers
Number of adult and children newly enrolled in HIV care who are started on treatment for latent TB infection, isoniazid preventive therapy, expressed as a proportion of the total number of adults and children newly enrolled in HIV care during the reporting period.	Pre-ART register (all newly enrolled should be registered on pre- ART register)
Number of facilities providing ART services for people living with HIV with demonstrable infection control practices that include TB control, expressed as a proportion of the total number of facilities providing ART services.	Facility visits as part of regular supervision or external review
Demonstrable infection control measures include a written infection control plan, a person responsible for implementing TB infection control, a well-ventilated waiting area, identification and separation of TB suspects on arrival and monitoring of TB cases among health care workers.	
Indicators to be reported by the NTP	
Number of TB patients registered during the reporting period who had an HIV test result recorded in the TB register, expressed as a proportion of the total number of TB patients registered during the reporting period. It includes TB patients who were known to be HIV-positive before being diagnosed with TB as well as TB patients with a negative HIV result from previous testing that was acceptable to the clinician (e.g. done in the last 3-6 months in a reliable laboratory).	TB register
Number of registered TB patients with a documented HIV status on TB register who were HIV-positive, expressed as a proportion of all registered TB patients with documented HIV status over the reporting period.	
Number of HIV positive TB patients who were started on or continued previously initiated CPT, during TB treatment, expressed as a proportion of all HIV-positive TB patients registered over the reporting period.	
Number of HIV positive TB patients who were started on or continued previously initiated ART during their TB treatment, expressed as a proportion of all HIV positive TB patients registered over the reporting period. This figure should be equivalent to the one reported by the NAP and	TB register
entail reconciliation of data between the two programmes.	

Annex 1

WHO clinical staging of HIV disease in adults, adolescents and children

Adult	Children	
Clinical stage 1		
 Asymptomatic Persistent generalized lymphadenopathy 	 Asymptomatic Persistent generalized lymphadenopathy 	
Clinical stage 2		
 Moderate unexplained weight loss (<10% of presumed or measured body weight) Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media, pharyngitis) Herpes Zoster Angular cheilitis Recurrent oral ulceration Papular pruritic eruption Fungal nail infections Seborrheic dermatitis 	 Unexplained persistent hepatosplenomegaly Recurrent or chronic upper respiratory tract infections (otitis media, otorrhoea, sinusitis, tonsillitis) Herpes Zoster Linear gingival erythema Papular pruritic eruption Fungal nail infections Extensive wart virus infection Extensive molluscum contagiosum Unexplained persistent parotid enlargement 	
Clinical stage 3		
 Severe unexplained weight loss (>10% of presumed or measured body weight) Unexplained chronic diarrhoea for >1 month Unexplained persistent fever (intermittent or constant for >1 month) Persistent oral candidiasis Oral hairy leukoplakia Pulmonary tuberculosis Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, bacteraemia) Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis Unexplained anaemia <8g/dl, neutropenia (<0.5 G/l) and/or chronic thrombocytopenia (<50 G/l) 	 Unexplained moderate malnutrition not adequately responding to standard therapy Unexplained persistent diarrhoea (≥14 days) Unexplained persistent fever (above 37.5 °C, intermittent or constant, >1 month) Persistent oral candidiasis (after first six weeks of life) Oral hairy leukoplakia Lymph node tuberculosis Peulmonary tuberculosis Severe recurrent bacterial pneumonia Acute necrotizing ulcerative gingivitis or periodontitis Unexplained anaemia <8g/dl, neutropenia (<0.5 G/l) and/or chronic thrombocytopenia (<50 G/l) Symptomatic lymphoid interstitial pneumonitis Chronic HIV-associated ling disease, including 	

Adult	Children
Clinical stage 4	
 HIV wasting syndrome <i>PcP</i> Recurrent severe bacterial pneumonia Chronic herpes simplex infection (orolabial, genital or anorectal of >1 month's duration or visceral at any site) Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) Extra-pulmonary tuberculosis Kaposi sarcoma Cytomegalovirus infection (retinitis or infection of other organs) Central nervous system toxoplasmosis HIV encephalopathy Extra-pulmonary cryptococcosis, including meningitis Disseminated nontuberculous mycobacterial infection Progressive multifocal leukoencephalopathy Chronic cryptosporidiosis Chronic isosporiosis Disseminated mycosis (extra-pulmonary histoplasmosis, coccidioidomycosis) Lymphoma (cerebral or B-cell non Hodgkin) Symptomatic HIV-associated nephropathy or cardiomyopathy Recurrent septicaemia (including nontyphoidal Salmonella) Invasive cervical carcinoma Atypical disseminated leishmaniasis 	 Unexplained severe wasting, stunting or severe malnutrition not responding to standard therapy <i>PcP</i> Recurrent severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, but excluding pneumonia) Chronic herpes simplex infection (orolabial or cutaneous of >1 month's duration or visceral at any site) Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) Extra-pulmonary tuberculosis Kaposi sarcoma Cytomegalovirus infection (retinitis or infection of other organs with onset of age >1 month) Central nervous system toxoplasmosis (after the neonatal period) HIV encephalopathy Extra-pulmonary cryptococcosis, including meningitis Disseminated nontuberculous mycobacterial infection Progressive multifocal leukoencephalopathy Chronic cryptosporidiosis (with diarrhoea) Chronic sosporiosis Disseminated endemic mycosis (extra-pulmonary histoplasmosis, coccidioidomycosis, penicilliosis) Cerebral or B-cell non-Hodgkin lymphoma HIV-associated nephropathy or cardiomyopathy

Annex 2: TB Registers and Reporting forms

Annex 2.1: Request for examination of biological specimen for TB (TB-05)

	nit:			Date	e of request:	-		
Patient name	e:					_		
Age (years):	Dat	te of birth:		Sex:	🔲 Male		Female	
Patient addre	ess:							
			Те	lephone:				
Previously tr	eated for TB:	Yes	No		Inknown			
HIV Status:		Positive	Negative		Inknown	>		
Reason for e	xamination: _							
🗔 Dia	agnosis	Presumpt	ive TB Reg. / OPD N	o				
E Fo	llow-up	Township	TB No/MDR-TB No		M	onth of	treatme	ent (
Specimen typ	pe:	Sputum	🗌 Other (spe	cify):				
Test(s) reque	ested:		py 🖂 Xpert MTB	/RIF				
Requested	l by Signature:		Drug susce	ptibility	🔲 Line pro	obe ass	say	
	d by Signature: Name:			ptibility	🔲 Line pro	obe as:	say	
Conta	d by Signature: Name: Designation:				Line pro	obe as	say	ZN
Conta Microscopy	d by Signature: Name: Designation: act phone no. : results (to be o		laboratory) Visual					ZN
Conta	d by Signature: Name: Designation: act phone no. :		laboratory)		uramin			
Conta Microscopy Date of specimen	d by Signature: Name: Designation: act phone no. : results (to be of Laboratory serial	completed in Specimen	laboratory) Visual appearance (blood-stained, mucopurulent or	Au	uramin Result (t		2)	ZN
Conta Microscopy Date of specimen	d by Signature: Name: Designation: act phone no. : results (to be of Laboratory serial	completed in Specimen	laboratory) Visual appearance (blood-stained, mucopurulent or	Au	uramin Result (t		2)	

Annex 2.2: Laboratory register for smear microscopy and X-pert MTB/RIF (TB-04)

Lab			Sex	Age	Patient Address	Treatment	OPD No. (or)	HIV Status	Previously treated		ination /pe			on results	
No.	Date	Patient's name	M/F		Phone No.	unit	TB No. (or)	(Pos/ Neg/	for TB	Dx	F-u		near oscopy	Xpert result	Remarks
				birth			DR No.	Unk)	(Y/N/Unk)		(Mth)	1	2	Lab. No	

Laboratory register for smear microscopy and X-pert MTB/RIF (TB - 04)

Annex 2.3: Laboratory register for culture, X-pert MTB/RIF and Drug susceptibility testing

Lab Serial No.	MGIT Serial No.	Date of Specimen received	Patient's Name	Sex	Age Date of Birth	Patient Address	Treatment Unit	TB Registered No/DR-TB Suspect No	HIV Status (Pos/ Neg/ Unk)	Patient prreviously treated for TB (Yes/ No/Unk)	Date of Specimen collected	Date of Specimen inoculated	Re Dx	F-L Mth

Laboratory register for culture, Xpert MTB/RIF and Drug susceptiblity testing

Sn	near	GXP ^a		Cul	ture ^b	6												1			LPA			
		GXP Lab No.	So	olid	Lic	quid	Identification		Resu	lts of	drug	susce	otibili	ty tes	ting(DST)	M	utatic	on			Date Results	Remarks
A	В	T/RR/TI/N/I	A	В	A	В		H	R	E	s	AMK	KM	CM	FQ			HR	Н	R	No Mutation	NTM	reported	Remarks
-																10								
	-						v																	
													_							_				

Laboratory register for culture, X-pert MTB/RIF and Drug susceptibility testing (continued)

Annex 2.4: TB treatment card (TB-01)

TUBERCULOSIS TREATMENT CARD (TB - 01)

Name		Phone	No.									nship th faci									
Complete address (Perm	anent)						_														
(Temp Sex M□ F□ Age	orary) Date of Birth										Pul	monar	yП			Extr	ase a Pu	Imona	ry 🗖		
Name and address of 1.	DOT Provider								-							(Spe	ecify)				
2.	DOT Supervisor																				
3.	Contact Person									-		pes of		atien							×
INTENSIVE PHASE - Pro				□ Heal	th Stat	errec ff (HS	5)					w apse nsfer i			Т	reate	ment	after f after l revious	FU		
	etreatment Regimen	Childhood Regime		D Priva				PP)							ι	Jnkn	own	previo	us tre	eatme	ent 🗖
	Previously Treated	All TB case<15 Yrs		Com Othe												_					
TE	Cases		1		(spe	city).															
					R	esult	s of I	Exan	ninati	on			F	Result	of	ultu	re ar	d DS1	-		
			Mont	h .	Smear			-		t Res	ult	Cu	ture	result	T	1	DST		L	PA	Weight
			WOR			No.		-		Lab	_			ab No	-		S	E	н	R	(kg)
								-							-	1	+	-			
(HRZE) (HR) Z S(E) (HI	RZE) (HR) Z E S ((HRZE) (HRZ) (HR) Z													-		1	1			
				-				-				-			1	1				1	
(HR) = isoniazid and rifar	npicin Z = pyrazinamid	le E= ethambutol													-		-				
S = streptomycin (HRZE	E) = 4FDC (HRZ) = 3F	DC						+							1		1				
															-	-	-	-		-	1
																		_			1
																1					
																-	-	1			1
			L												-				1		
			Culture re									ninated)								
Tick appropriate box afte	the drugs have been a											ted. RF	= Rif	resistar	nt. TI=	MTE	3 (+) /	Rif resis	tant is	invalio	d or No resul
Day Day												100,00		T						Т	otal doses
Month 1 2 3 4	5 6 7 8 9	10 11 12 13	14 15	16 1	7 18	19	20	21	22	23	24 2	25 26	27	28	29	30	31	Number this n		5	of IP given
					-										1						
					-						-					-	-			-	
					-			-		-	-	-			-	-	-+			-	

Please turn over for continuation phase

TB treatment card (TB-01) (continued)

Childhood Regimen Initial Regimen Retreatment Regimen (5 months) (4 months) (4 months) (HR) (HR) (HRE) (HR) E Day Number Total number 22 23 24 25 26 27 28 15 16 17 18 19 20 21 29 30 31 doses 1 2 3 4 5 6 7 8 9 10 11 12 13 14 doses given this month Month

II. CONTINUATION PHASE - Prescribed regimen and dosages

Enter () on day of directly observed treatment. For a self-administered regimen, enter (X) on day when drugs are collected. Any time drugs are given for self-administration, draw a horizontal line (-------) through the number of days' supply given.

Observations: eg. CXR findings, side effect, any action by BHS, other co-morbidities, pregnancy, etc.:

TB/HIV Activities		Status		Date
HIV tested	D Positive	Negative	Unknown	
CPT received				
ART received				

Treatment outcomes	
Date of decision	
Cured	
Treatment completed	
Treatment failure	
Died	
Loss to follow up	
Not evaluated	
Move to SLD treatment	

Annex 2.5: Township TB register (TB-03)

					•				Туре	of Patients				тв
-	Township TB		Sex	Age	Address	Health Facility			Previously t	reated patient		Previous	Transfer	Site
Date	No.	Name	M/F	DOB	Phone No.	Refered from (HS/PP/C/Oth)	New (N)	Relapse (R)	Treatment after failure (F)	Treatment after loss to follow-up (LFU)	Others previously treated (O)	treatment history unknown (Unk)	in (T)	P/ EP
		*												

Township TB Register (TB - 03)

Township TB register (TB-03) (continued)

				-						Tov	wnshi	p TB I	Regist	er (TB	- 03)								
							Smear	(S), Xp	ert MTI	B/RIF (N	() resul	ts or Cu	lture (C)			Treatment	outcomes	(Choose of	one with D	ecision Date	e)	
	ent regimenter start	ens (choose ed date)		HIV vities	At the	ime of	TB diag	nosis	Month	2 or 3	Mo	nth 5		d of ment			Treat-	Treat-				Moved to second-	
Initial	Retreat- ment	Childhood			HIV Status	s	x	С	s	С	S	С	S	с	DST	Cured	ment Complete	ment	Died	Lost to follow-up	Not Evaluated	line treat- ment	Remarks
regimen	regimen	regimen	Date	Date	(Pos/ Neg/ Unk)		Lab No		Lab	No.	Lab	No.	Lab	No.								register	
				-					-														
	-		-			-			-		_									-			×
			-			-	-		-			_		_						-			
						-			-		-												
	ļ						-		-			-				1							
						-		I	-				-										
											-												
							_																
									-														
			<u> </u>			-					_								1				
							1																

Township TB Register (TB - 03)

Annex 2.6: Quarterly report on TB case registration (TB-07)

Block 1: All TB cases registered during the quarter except Transfer in patients

Type of patient					Re-tro	eatment C	ases				
Type of disease	Ne	w	Reli	apse	(excl	ly treated uding pse)	prev	nown vious nt history	То	tal	Grand Total
	M	F	M	F	M	F	M	F	M	F	
Pulmonary, bacteriologically confirmed							1. 2010			1	
Pulmonary, clinically diagnosed											
Extra pulmonary, bacteriologically confirmed									0		
Extra pulmonary clinically diagnosed											
Total TB Case											

Block 2: All new and relapse cases (bacteriologically confirmed or clinically diagnosed) registered

ype Age Sex	0-	4	5	.9	10-	14	15-	-24	25-	-34	35	-44	45	-54	55	-64	2	65	To	tal	Grand
	м	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F	Total
New																					
Relapse																					
Fotal																					

Childhood TB Meningitis by Age group and Sex

0 -	- 4	5-	- 9	10 -	- 14	To	tal	Grand
М	F	M	F	M	F	м	F	Total
							1970 - C	

Block 3: Laboratory diagnostic and follow-up activity

	N	TP	M	MA	P	SI	Т	otal
	S	X	S	X	S	X	S	X
(a)Patients with presumptive TB for Diagnosis (Dx)								
(b)Number of Patients with positive bacteriological results out of Diagnosis (Dx)								
(c)Number of patients examined for follow-up		Har and		Training Miles		The second second	1	Party and
(d)Number of positive patients out of follow-up		STATISTICS.		BROIL		Contraction of the		Sector Sector

Block 4: TB/HIV activities (all TB cases registered during the quarter)

Number of patients tested for HIV or/and known HIV status (Pos / Neg) at the time of Diagnosis registered in the Township TB register	No. of HIV-positive TB patients	HIV-positive TB patients Start CPT and ongoing CPT	No. of HIV + TB patients Start ART and ongoing ART

Remarks - IR () cases RR () cases CR () cases Total () cases

Countersigned by: Signature: ______ Signature: _____

Name: ____

Designation:

Name: ____

Designation:

Annex 2.7: Quarterly report on the outcome of TB patients registered 12-15 months earlier (TB-08)

Quarterly report on the outcome of TB patient registered 12-15 months earlier (TB - 08)

Name of township Township code no.	Patients registered during	Date of completion of this form: signature
Name of Township TB coordinator		· · · · · · · · · · · · · · · · · · ·

	No. of			Т	reatment	t outcomes	6	
TB patient type	cases registered	Cured	Treatment completed	Failed	Died	Lost to follow- up	Not evaluated	Moved to second-line drug
Block 1(A). All TB cases registered during the qu	arter of the p	revious y	ear					
1. Bacteriologically confirmed new cases								
2. Bacteriologically confirmed relapse cases								
3. Clinically diagnosed, new and relapse								
4. Retreatment (excluding relapse)								
Block 1(B). All HIV positive TB cases registered of	during the qu	arter of t	the previous y	year				
1. Bacteriologically confirmed new cases								
2. Bacteriologically confirmed relapse cases								
3. Clinically diagnosed, new and relapse				1				
4. Retreatment (excluding relapse)								
	1							
Block 1(C). All childhood cases registered during	the quarter of	of the pre	evious year					
All childhood TB cases (< 15 Yrs)								

Block 2: TB/HIV activities (all TB cases registered during the quarter of the previous year)

HIV-positive	HIV-positive	HIV-positive
TB patients	TB patients on CPT	TB patients on ART

Countersigned by:

Designation:

Annex 3: HIV registers and forms Annex 3.1: TB Screening and IPT Evaluation Register

			< 1	l5 yrs	≥ 1	l5 yrs		1st v	risit		1	B screen	ing				IPT	evaluatior	1 **	II Deci		
No	HIV Reg No.	Name	Male	Female	Male	Female	Newly enrolled	Calendar Year	Current Quarter	Cough (any)	Fever	Weight loss / Pailure to thrive	Night sweats	Lymph node enlarged	TB Contact History (Age<5yrs)	Refer for TB Diagnosis (Date) *	Prior or Current Anti-TB treatment	Prior or Current IPT	Chronic liver D/s or Alcohol use	Yes/ No	Date	Remark
1																						
2																						
3																						
4																						
5																						
6																						
7																						
8																						
9																						
10																						
11																						
12																						
13																						
14																						
15																						
16																						
17																						
18																						
19																						
20																						

Township Quarter

* In the column "Refer for TB diagnosis", if refer, please fill the referral date. ** In IPT decision, If yes, please fill *IPT started date*, and if no, please fill (a:

Not eligible, b: Provider / Doctor decision, c: Patient decision, d: others)

Annex 3.2: pre-ART register

[1	2	3	4	5	6		7			8	3		9	9		10	11	12
	Date 1st /isit at :he	Registration		Age	Sex: M/F	Status at		when appli	table Tf: Rx start: month/year started and TB			l sta 3	lf yes, rec exposed i	Pregnan ord EDD, infant No.	ANC No. a	nd HIV –	Risk factor code	Date medically eligible for	ART start date. (transfer to
	ine Ilinic	number	Name and address			enrolment*	CTX Start month/year	INH start month/year	started and TB reg no.	_	-	_	Preg 1	Preg 2	Preg 3	Preg 4	10 **	ART	ART register)
1																			
2																			
з																			
4																			
5																			
6																			
7																			
8																			
9																			
10																			
11																			
12																			

PRE-ART REGISTER page 1 (left)

* Status at entrolment (Pregnant; Post Partum; TB Rx; Other). If pre-ART transfer in patient, write TL. * Entry point: 1-VCT; 2-PMTCT; 3-STI; 4-TB; 3-Outpatient; 6-Inpatient; 7-Private; 8-NGO; 9-Self referred; 10-Drug Treatment Unit; 11- Others-Write code TR if the patient was transferred in on ART ** Risk factor for HIV; 1-Heterosexual; 2-Men who have sex with men; 3-Sex work; 4-Injecting drug use (IDU); 5-Blood transfusion; 6-Mother to child; 7-Unknown

PRE-ART REGISTER page 2 (right)

										Quart	erly follo	ow-up	status										
	Ye	ear	_		Ye	ear	_		Ye	ar	_		Ye	ar	_		Ye	ear	_		Ye	ar	-
Q1 Jan-Mar	Q2 Apr-Jun	Q3 Jul-Sep	Q4 Oct-Dec	Q1 Jan-Mar	Q2 Apr-Jun	Q3 Jul-Sep	Q4 Oct-Dec	Q1 Jan-Mar	Q2 Apr-Jun	Q3 Jul-Sep	Q4 Oct-Dec	Q1 Jan-Mar	Q2 Apr-Jun	Q3 Jul-Sep	Q4 Oct-Dec	Q1 Jan-Mar	Q2 Apr-Jun	Q3 Jul-Sep	Q4 Oct-Dec	Q1 Jan-Mar	Q2 Apr-Jun	Q3 Jul-Sep	Q4 Oct-Dec
Total TB Seen at l				-												-							
Seenau	east one	emr						J				J]				J			
CD4-re 	cord las id not h not see	t CD4 in ave visit n in the d out (re	quarter schedu	led for t rter, but	hat qua	rter					Record			visit in l	last qua	rter							
DEAD-	record	uate																					

Annex 3.3: ART register

ART REGISTER (1)

							Month:			Year			_								
1	2	3	4	5	5	6	7	8	9	10	11	12	13	14	15		16	17		18	
																			Treat	tment sul	bstituted
			Age	Se	≥x			Status	at start o	of ART	Fill ir	n when ap	plicable		PM	тст				nin 1st lin	e drugs
							Treatment						TB Rx					ART Regimen	1		1
							Supporter's						Starting					Started	1		1
Date of						Patients Address	name and		WHO		CPT	IPT	date						Date		1
Start of	Registratio					and	contact		Clinical		Starting		and TB reg							Reason **	
ART	n number	Name		Μ	F	Contact number	number	Weight	Stage	CD4	date	date	No.	Preg 1	Preg 2	Preg 3	Preg 4 >		uted	**	Regimen
																					L
							_														
																		1			
																					(
																		1			
																			<u> </u>		
																			L		L

**Reasons for substitution within first line treatment: 1-toxicity or side effects; 2-pregnancy; 3-newly diagnosed TB; 4-new drug available; 5-drug out of stock; 6-others.

*** Reasons for switching to second line treatment: 1-toxicity; 2-pregnancy; 3-newly diagnosed TB; 4-new drug available; 5-drug out of stock; 6-clincial treatment failure; 7-others; 8-immunological failure; 9-virological failure.

Reasons for stopping ART: 1- toxicity side effects; 2-pregnancy; 3-treatment failure; 4-poor adherence; 5-illness hospitalisation; 6-drug out of stock; 7-patient's decision to stop; 8- planned interruption; 9 others.

	19		20													21												22
			Cause of	Monthl	y visits	: • 1st	t row	: write	patier	nt outco	ome: o	n treati	nent re	ecord o	urrent	regimen	code i	f patier	nt pick	ed up A	RT drug	s; stop	ped (ST) if ART	was st	opped	by the	
reatmer	t Switche	d to 2nd	end of	doctor; r	missing	g (MIS)	if the	e patie	nt miss	sed the	scheo	luled vi	sit; los	t to fo	llow-up	(LFU) if	the pa	tient is	missir	ng for 2	-3 mon	ths; res	tart (RS)) if ART	was re	starter	d after a	n
	line		follow up	interrup	tion; tr	ansfer	red o	ut (TR)	; dead	(D); if t	the pa	tient w	as not	schedu	uled to	isit this	month	n (NA) .	Botte	om, 2no	d row:	Record	TB stat	tus at la	st visit	in las	t quarte	r
																												Rema
			Death/LFU																									
			/Transfer																									
itched	Reason**	Regimen	out	Week 2	mo.1	mo.2	mo.3	mo.4	mo.5 m	o. (6) m	10. 7m	o. 8mo.	9mo. 1	LOmo. 1	11 <mark>mo. (</mark> :	2)mo.1	5 mo.18	3mo.21	mo. (2	4) mo.2	7 mo.30	mo.33	mo. (36	5) mo.39	mo.42	mo.45	mo. (48	5)
			D/L/T							CD4					C	D4			CI	04			CD)4			CD	4
			//																									
			D/L/T																									
			//																									
			D/L/T																									
			//																									
			D/L/T						_																			
			//																									
			D/L/T																									
			//																									
			D/L/T																									
			//																									
						Adult :	1st -	ine re	Child 1	st - line	e regi	nens			A	dult 2nd	- line i	regime	ns									
			D - Death		1	1a = AZ	ZT-3T	C-EFV	4a = Az	ZT-3TC-	EFV				2	a = AZT-	3TC-LP	PV/r										
			L - Lost to f	ollow up	1	1b = Az	ZT-3T	C-NVF	4b = Az	T-3TC-	NVP				2	b = AZT-	3TC-AT	TV/r										
			T - Transfe	rout	:	LC=TD	F-3TC	-EFV	4c = AE	SC-3TC-	-EFV				2	c = TDF-	3TC-LP	PV/r										
					1	1d = TC	DF-3T	C-NV	4d = AB	3C-3TC-	-NVP				2	d = TDF-	3TC-AT	TV/r										
															2	e =												
															2	fe =												

Annex 3.4.1 ART treatment card

mater

D. Mayeta SLO, Date	incluincation Dat	e (Write complete	e infor	matior	1)	
Registration Number: [Date: Clinic code (3#) / Adult / child co	ode (2#) patient register (5		ן			
Name of patient:		2020/2020				
Age: Date of Patient's phone number:	of birth:/]/0000	Sex	<u>м</u>	ale 🗌 Fe	mal
Address:						
Village/City:	Township:	Stat	e or R	egion:		
Treatment supporter's name	e (if applicable):			-		
Treatment supporter's addre	Acc. 1845 - 1843			11		
Treatment supporter's phon						
Date HIV + test:	and address of the second second	ice:				
Entry Point (services referring 5-Outpatient 6-Inpatie 11-others	nt 7-Private 8-NG	60 9-Self referred	итст 10-1	3-ST Drug tre	TI∏ 4-TB atment Un	it
Outpatient 6-Inpatie 11-others Patient transferred in Pre Patient transferred in on A	ART care from another HIV	90 9-Self referred er clinic care/ART clinic	итст 1 🗖 10-1	☐ 3-ST Drug tre	TI∎ 4-TB atment Un	it
-Outpatient C-Inpatie 11-others Patient transferred in Pre Patient transferred in on A Name previous clinic:	ART care from another ART from another HIV D	O □ 9-Self referred ar clinic care/ART clinic iate transferred in :	10-1	Drug tre	atment Un	it
-Outpatient 6-Inpatie 11-others Patient transferred in Pre Patient transferred in on A Name previous clinic: 2. Personal	ART care from anothe ART from another HIV D History	GO 9-Self referred er clinic care/ART clinic ate transferred in : 3.	Famil	Drug tre	atment Un	
	ART care from another ART from another HIV D History	O □ 9-Self referred ar clinic care/ART clinic iate transferred in :	Famil	Drug tre	ory	
	ART care from another ART from another HIV D History	O O	Famil	Drug tre	ory	inwe
	ART care from another ART care from another ART from another HIV D History event event (MSM) (MS	O O		y Histo Histo Age		inwe AF
	ART care from another ART care from another ART from another HIV D History evenal evenal (NSM) (com (CAM) (from (NSM)) (from use (IDH)) anotherion in child	O G		Drug tre	ory urried With cable HIV +/-	
	ART care from another ART care from another ART from another HIV D History Proval (MAN) (KSM) (KOM) (Intro use (IDII)) anschielon m child m	O G		y Histo Histo Age	ory rried Uwin cable HIV +/- un-	inwe AF
	ART care from another ART care from another ART from another HIV D History His	O G		y Histo Histo Age	ory rried Uwin cable HIV +/- un-	inwe AF
	ART care from another ART care from another ART from another HIV History Prisal with men (MSM) & (SMA down use (IDI1) assiduering brokiering br	O G		y Histo Histo Age	ory rried Uwin cable HIV +/- un-	inwe AF
	ART care from another ART care from another ART from another HIV D History His	O G		y Histo Histo Age	ory rried Uwin cable HIV +/- un-	inwe AF
	ART care from another ART care from another ART from another HIV History evilation evilation (MSM) (c (SM) (c (SM)	O G		y Histo Histo Age	ory rried Uwin cable HIV +/- un-	inwe Af

Drugs and duration

5. Exposed-infant follow-up xposed-Infant DOB Infant CPTstat- HIV Test Final ()f cofirmed Name of the treatment unit: -----Name/No feeding ed date status infected) type/ artum 🗖 Other 🛛 practice result/ Unique ID Township: date State/Region:-6. Clinical and Laboratory WHO CD4 count Date (dd/ Weight Height Perfor-(or % In mm Stage (kg) (ft.) mance A/B/C* yy) children) At 1st Visit in clinic At ART medical eligibility child At start of ART child AT 6 months ART child At 12 months ART child AI 24 months ART "Performance scale" A Normal activity, B bedridden K50% of the day during last month: C bedridden >50% of the day during last month 7. Antiretroviral treatment SUBSTITUTION within 1st line, SWITCH to 2nd line, STOP, RESTART Treatment Started Substitution, switch Reason Date Date restart New regimen or stop (code) Reasons SUBSTITUTE/SWITCH : 1 toxicity, 2 Pregnancy, 3 new TB, 4 new drug, 5 out of stock, 6 others (specify) Reasons for SWITCH only failure to, treatment, 7 clinical, 8 8. Treatment for TB disease during HIV care **Disease Classification TB Regimen TB** registration Disease Platmonary TR/ FP Bacteriologically Confirmed Clinically diagnosed-St D nitial Daniman Township: TB Clinic Clinically diagnosed-Onin Sensitivity TB number : -Treatment outcome Cure Rx completed Stating date 00/00/1 Loss П 9. End of Follow-up for Antiretroviral therapy Transferred out Date of death Date last visit : Date :

New clinic

Annex 3.4.2 ART treatment card

				-	10.P	atient HIV	care & Anti	retrovir	al treatment Follow -	up			
Date of visit*	Date next visit	Weight (kg) and Height	WHO stage	Pregnancy (Y/N, EDD) or FP/BS method	Opportunistic infections- code [*] If child, nutritional problems	СРТ	TB status	IPT	Anti-retroviral drugs and dose prescribed	Adherence to ART* >95%, 80-95% , <80%	ART side effects- code*	Lab results when available	Referred to CoC
<u> </u>													
<u> </u>													
								-					

" Instructions and codes:

Date: Write the date of actual visit starting rom the 1st visit for HIV care. ALL DATES ; DD/MM/YY

FP: Family planning ; 1 condoms: 2 oral contraceptive pills, 3 injectable/implantable hormones, 4 diaphram/ cervical cap, 5 intrauterine device, 6 vasectomy/tubal ligation/hysterectomy

TB status: No signs = no signs or symptoms of TB

Presumptive TB = TB refer or sputums sent (Record sputum sent & results in lab column; record referral in Refer col)

Not done (ND) = not assessed for whatever reason

Opportunistic infection: Enter one or more codes—Tuberculosis (TB); Candidiasis(C); Diarrhoea (D); Cryptococcal meningitis (M); Pneumocystis jerovici pneumonia (PCP); Cytomegalovirus disease (CMV); Penicilliosis (P); Herpes Zoster (Z); Genital herpes (H); Toxoplasmosis (T); Other—specify

Adherence: Check adherence by asking the patient if he/she has missed any doses. Also check the bottle/blister packet. Write the estimated level of adherence is (e.g. > 95% - <3% does missed in a period of 30 days; 80-95% - 3 to 12 doses missed in a period of 30 days; <80%=>12 doses missed in a period of 30 days for 60 tablets/ 30 days)

Side effects: Enter one or more codes—S=Skin rash; Nau=nausea; V=Vomiting; D= Diarrhea; N= Neuropathy; J=Jaundice; A=Anaemia; F=Fatigue; H=Headache; F=Fever; H/S=Hypersensitivity; Dep=Depression; P=Pancreatitis; L=Lipodyatrophy;

Annex 4: IPT registers and forms Annex 4.1: IPT register

IPT.						IPT		Da	te of n	nonthl	y drug	g issue		IPT		Remarks
Reg. No.	Clinic Reg. No. (ART No.)	Name (in full)	Age	Sex (M/F)	Address	registration date (DD/MM/YY)	Dose	Month 1	2	3	4	5	6	discontinu ation date (DD/MM/ YY)	Outcome †	Remarks
						Ι										

-

Page Summary for	Treati Registi		Treatment	Outcomes (to be reported 1 year after	† <u>For TB Prophylactic Treatm</u>	ent Outcome Definitions	
quarterly report	Adults ≥15 years	Children <15 years	Completed for 6 months	Incomplete (Discontinue due to side effect, by patient, Died)	TB Disease	Completed \underline{Tx} – completed treatmet Incomplete \underline{Tx} – Discontinue due t	
Respective township						TB Disease – diagnosed as TB dise	ase while on IPT
Other township							

Annex 4.2: IPT card

	ISONIAZID PREVENTIVE THERAPY CARD FOR CHILDREN AND ADULT																																	
		Hea	alth	Fa	cilit	у_									Tow	nshi	р					D	istri	ct			R	egio	n/St	ate _				
		Nar	ne												Age SexAddress																			
	Father's name Cont									onta	ct T	owns	ship	тв	Num	nber_				_ IF	PT S	r. No	o											
	IPT starting date:// daily doseExpected stop date//																																	
	Completion date of Isoniazid Preventive Therapy/																																	
Month	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	Doses	Wt in Kg	Remarks
	\square																																	
	\square																																	
	\square	\square																																

Annex 5: Cross referral forms

Annex 5.1 Three inter link referral form

3 Interlinked Patient Monitoring <u>System</u> Department of Health Referral Form

Referred from(If depart ,	/ organization has registration No) Date of referral// edical history + risk factor)
Reason for referral	n 6. PMCT
1. HIV testing / HCT	6. PMCT 7. OI & STI treatment
 CD4 testing Viral Load testing 	8.IPT
	04 & VL 9. TB (diagnosis & treatment)
5. Antiretroviral therapy (ART)	
	e after discussion and agreement from the center where patient is
- Official seal	Signature Name Designation Department / organization
Name of Department/Organization _	(Referred center registration No)
Official seal	Signature Name Designation Department / organization:

Referral form to be filled in duplicate (using carbon less copy). Record of in and out referrals should be maintained by both for proper follow up, while keeping it confidential.

Annex 5.2: TB/HIV cross referral form

TB-HIV Cross Referral Form													
				, '									
					Township								
Patient's Name			Age		Sex								
Referred fro	m NAP/NTP	to	NAP/N	ITP	Referral No:								
Registration No:			Date o	f referral									
Descent for Deferred													
Reasons for Referral Diagnosis and Treatment of TB Cotri prophylaxis													
Diagnosis and Tre	eatment of TB]		Cotri pro	phylaxis								
HIV Testing and G	Counselling (HTC)	1		IPT intiat	ion								
Assessment & En	rollment for ART	1		CoC									
		10											
Treatment for Ol	S			others									
			Remar	ks:									
Signature													
Name													
Designation													
×													
TB-HIV Cross Referral Feedback Form													
	TB-HIV Cross	Referral F	eeub										
			_		Township								
Patient's Name					Sex								
Feedback fro		to	NAP/N		Referral No:								
Registration No:			Date o	of received									
	Action(s)	taken for Re	ferred	case									
Diagnosis of TB: sputum	ex. 💭	CXR	_		Provide anti TB								
blughosis of the spatality		Chit	· · ·		Started date:								
HTC: Testing		Counselling		-	surred dute.								
Enrolled for ART		started ART	·	4	started date:								
Treatment for Ols		started ARI			started date.								
Provide Cotri prophylaxis													
Provide IPT		Charles I. I.											
athers (an a -!f.)													
others (specify)		Started date	e:										
others (specify)		Started dat		emarks:									
		Started dat		emarks:									

Annex 6: Reporting forms for TB/HIV activities Annex 6.1: Quarterly Reporting Format for TB/HIV Activities to be reported by NTP

Block B: Reporting for TB team					
		Nun	nber		
	0-	14	≥	15	Data Source
	М	F	М	F	
Number of TB patients (<u>New+ replase)</u> registered during					Township TB register
the reporting period					Township TB register
Number of TB patients (New+ replase) registered during					
the reporting period who had an HIV test result recorded in					Township TB register
the TB register					
Number of TB patients (<u>New+ replase)</u> registered during					Township TB register
the reporting period with documented HIV-positive status					
Number of HIV-positive TB patients (New+ relapse),					
registered during the reporting period, starting or					Township TB register
continuing CPT treatment during their TB treatment					
Number of HIV-positive TB patients (New+relapse),					
registered during the reporting period, who are stared on					Township TB register
or continue previously initiated ART during TB treatment					

Signature	 Signature	
Name	 Name	
Designation	 Designation	
Program	 Program	

* Total number of incident TB cases (New+replase) of a reporting unit for a defined reporting period will be equal to the total number of patients of <u>Block 2 of TB 07</u> of the corresponding reporting period.

Annex 6.2. Quarterly Report for TB/HIV collaborative activities

NDS/STD team/ HIV clinic											0	uarter		
B team											Y	'ear _		
ownship/District							0.03							
		Newly e	nrolled		1st	visit for c	alender	year	Head	count in o	current o	quarter		
Block A: Reporting for AIDS/STD team/ HIV clinic	0-	14	≥	15	0-	-14	2	15	0-	14	2	15		
×.	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female		
lumber of PLHIV attended HIV care during the reporting veriod									40					
umber of PLHIV screened for TB during reporting period							a							
lumber of PLHIV referred for TB diagnostic evaluation			-											
Number of PLHIV diagnosed with active TB diasease and egistered for TB treatment	7			8					/					
Number of PLHIV received IPT evaluation														
umber of PLHIV who were eligible for IPT												•		
Number of PLHIV who were given IPT in reporting period														
PT outcome reporting for patient registered in IPT during he same quarter, one year earlier	during s	lumber reg same quar year earlie	ter, one		Complete 6 monti		(Discor	Incomplete ntinue due lost to fol	to side	TB dise	ase while			

		New and relap	sed TB patients		
Block B: Reporting for TB team	0-	14	2	15	Data Source
	Male	Female	Male	Female	1
Number of TB patients registered during the reporting period					Township TB register
Number of TB patients registered during the reporting period who had an HIV test result recorded in the TB register					Township TB register
Number of TB patients registered over the reporting period with documented HIV-positive status					Township TB register
Number of HIV-positive TB patients registered over the reporting period, starting or continuing CPT treatment during their TB treatment	·				Township TB register
Number of HIV-positive TB patients who are already on ART or started ART during TB treatment					Pre-ART, ART, TB register

Signature	 Signature	
Name	 Name	
Designation	 Designation	
Programme	 Programme	

Annex 7. Supervision Check Lists Annex 7.1 Supervision Check List for TB/HIV collaborative Activities in TB Centres/ Clinics

Township Profile related to TBHIV

Township population -

Total registered TB patients in previous year (minimum estimated number for Determine/yr)-

HIV positive rate in last year (for estimated number for Uni-gold and Stat Pak /yr)---

Infection Control

Space and ventilation status of waiting area, TB consultation room and laboratory

Vinyl for cough Hygiene displaying at OPD

Surgical masks for all TB patients

N95 for Health care workers

Human Resource and capacity building

Appointed staff versus number of staff mobilized at the TB center

Number of staff received TBHIV training among appointed staff

Recording

Recording status of TBHIV data in TB 03 (HIV status and test dates, GXP result, CPT, ART dates for TBHIV patients)

Recording status of TBHIV data in TB 04 and Township TB code

Reporting and data analysis

Consistency of TB 03, TB 07 and quarterly TBHIV activity report

Trends of proportion of known HIV status, proportion of HIV positive cases, proportion of TBHIV patients on CPT and ART for 4 Quarters

Outcomes data of TBHIV patients TB 08 and its trends for 4 Quarters

Referral and linkage system

Mapping of service delivery points for HIV care services (ART centers and ART decentralized sites)

Filing system of referral register and feedback form

Logistics, store and stock management

Store condition (temperature chart, pallets, and bin card)

Estimated monthly consumption versus stock in hand and expire dates for all test kits

Annex 7.2 Supervision Check List for TB/HIV collaborative Activities in ART Centers/ ART DC site/AIDS-STD team

Township Profile related to TBHIV

Township population (Census) Total No of PLHIV on ART (NAP + IPs data) Total No of PLHIV enrolled for HIV care during this month No of HIV +ve TB patients who received both ART and TB treatment during this month No of PLHIVs who were given IPT in reporting period

Infection Control

Space and ventilation status of waiting area, HIV consultation room and laboratory

Surgical masks for open cases

N95 for Health care workers

Human Resource and capacity building

Appointed staff versus number of staff supposed to be at the center

Number of staff received TBHIV training among appointed staff

Recording

Pre ART care register (HIV enrollment register) ART register HIV care and Antiretroviral treatment record card (White card) OPD TB screening register IPT register ART monthly report

Reporting and data analysis

Consistency of TB screening register, HIV care register and quarterly TBHIV activity report

Quality of service and outcomes data from TB/HIV activity report

Referral and linkage system

Mapping of service delivery points for HIV care services (ART centers and ART decentralized sites)

Filing system of referral register and feedback record.

Proper filling of referral and in referral record

Logistics, store and stock management

Store condition (temperature chart, pallets, and bin card)

Estimated monthly consumption versus stock in hand and expire dates for drugs.

Annex 8. Quarterly Consumption Report and Request for HIV Tests

	National TB Program Quarterly Consumption Report and Request for HIV Tests														
Reporting period:Quarter,Year.															
State/Region:TBHIV project townshipDate of completion of report									-						
		Opening		ty	Qtv use	d/issued	Closine	g balance	-	monthly	Maximum	Qty need			
HIV Test	Basic Unit	balance	rece	eived	~~~~				consu	Imption	Stock Qty	next qu	arter		
	A			В		С	D=(4	\+B-C)	E=	=C/3	F=Ex3	G=F-	D		
Determin	Test														
Uni-gold	Test														
Stat-pak	Test														
Monthly (Consumption	n		_						_			_		
HIV Test	Basic Unit	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec		
Determin	Test														
Uni-gold	Test														
Stat-pak															
* The form	nulas are giv	en for the	reporting	g period o	of 3 month	s.	•	•	•	•	•	•			
Prepared	by:														
Signature	:														
Name:															
Designati	on:														
Date:															